Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Chile | Croatia | France | Hong Kong | India | Indonesia | Ireland | Korea | Pakistan | Taiwan | Turkey | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Obesity|Other|Overweight|Sleep Apnea, Obstructive
Phase 2: Radiodermatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GRA.05.SPR.0001 | P2 |
Unknown Status |
Radiodermatitis |
2025-04-30 |
|
CTR20222427 | P3 |
Not yet recruiting |
Sleep Apnea, Obstructive|Obesity |
None |
|
CTR20200672 | P3 |
Not yet recruiting |
Obesity|Overweight |
None |
|
CTR20212274 | P3 |
Not yet recruiting |
Other |
None |